Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.

CONTEXT Deciding on the appropriate therapy for patients with malignant diseases mandates accurate tumor staging with whole-body coverage. Magnetic resonance imaging (MRI) and a combined modality including positron emission tomography (PET) and computed tomography (CT) provide whole-body tumor staging in a single session. OBJECTIVE To determine the staging accuracies of both whole-body PET/CT and whole-body MRI for different malignant diseases. DESIGN, SETTING, AND PATIENTS Prospective, blinded, investigator-initiated study of 98 patients (mean age, 58 years; range, 27-94 years) with various oncological diseases who underwent back-to-back whole-body glucose analog [18F]-fluorodeoxyglucose-PET/CT and whole-body MRI for tumor staging. The study was conducted at a university hospital from December 2001 through October 2002 and had a mean follow-up of 273 days (range, 75-515 days). The images were evaluated by 2 different, blinded reader teams. The diagnostic accuracies of the 2 imaging procedures were compared. MAIN OUTCOME MEASURES Correct classification of the primary tumor, regional lymph nodes, and distant metastasis (overall TNM stage) using whole-body PET/CT and whole-body MRI. Secondary outcome measures were accurate assessment of T-stage, N-stage, and M-stage by the 2 imaging procedures. RESULTS Of 98 patients, the overall TNM stage was correctly determined in 75 with PET/CT (77%; 95% confidence interval [CI], 67%-85%) and in 53 with MRI (54%; 95% CI, 44%-64%) (P<.001). Compared with MRI, PET/CT had a direct impact on patient management in 12 patients. Results from MRI changed the therapy regimen in 2 patients compared with PET/CT. Separate assessment of T-stage (with pathological verification) in 46 patients revealed PET/CT to be accurate in 37 (80%; 95% CI, 66%-91%) and MRI to be accurate in 24 (52%; 95% CI, 37%-67%) (P<.001). Of 98 patients, N-stage was correctly determined in 91 patients with PET/CT (93%; 95% CI, 86%-97%) and in 77 patients with MRI (79%; 95% CI, 69%-86%) (P =.001). Both imaging procedures showed a similar performance in detecting distant metastases. CONCLUSIONS The feasibility and diagnostic accuracy of the whole-body staging strategies of PET/CT and MRI are established. Superior performance in overall TNM staging suggests the use of [18F]-fluorodeoxyglucose-PET/CT as a possible first-line modality for whole-body tumor staging.

[1]  J. Debatin,et al.  Whole-body MR imaging in 30 seconds with real-time true FISP and a continuously rolling table platform: feasibility study. , 2001, Radiology.

[2]  R. Semelka,et al.  Liver lesion detection, characterization, and effect on patient management: Comparison of single‐phase spiral CT and current MR techniques , 1997, Journal of magnetic resonance imaging : JMRI.

[3]  R. Semelka,et al.  Focal liver lesions: Comparison of dual‐phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement , 2001, Journal of magnetic resonance imaging : JMRI.

[4]  D W Townsend,et al.  Dual-modality PET/CT tomography for clinical oncology. , 2002, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[5]  Thomas Beyer,et al.  Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  G. van Kaick,et al.  Magnetic resonance imaging to detect bone marrow metastases in the initial staging of small cell lung carcinoma and breast carcinoma , 1999, Cancer.

[7]  Yuji Nakamoto,et al.  Clinically significant inaccurate localization of lesions with PET/CT: frequency in 300 patients. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  Thomas Beyer,et al.  Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.

[9]  J. Galli,et al.  Role of magnetic resonance imaging in the staging of gastrointestinal neoplasms. , 2001, Seminars in surgical oncology.

[10]  N. Müller,et al.  Mediastinal nodes in bronchogenic carcinoma: comparison between CT and mediastinoscopy. , 1988, Radiology.

[11]  R. Tiling,et al.  Korrelation von FDG-PET und MRT/CT mit der Histopathologie in Primärdiagnostik, Lymphknotenstaging und Rezidivdiagnostik von Kopf-Hals-Tumoren , 2002 .

[12]  Thomas F Hany,et al.  PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. , 2002, Radiology.

[13]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[14]  M. Mix,et al.  Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. , 2001, Radiology.

[15]  S. Hain,et al.  FDG-PET as a "metabolic biopsy" tool in non-lung lesions with indeterminate biopsy , 2001, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  E. van Marck,et al.  Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma. , 1997, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[17]  Cyrill Burger,et al.  Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[19]  W. Hollinshead.  The head and neck , 1954 .

[20]  J. Debatin,et al.  Three-dimensional volumetric interpolated breath-hold MR imaging for whole-body tumor staging in less than 15 minutes: a feasibility study. , 2002, AJR. American journal of roentgenology.

[21]  P. Dupont,et al.  Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Douglas C McCrory,et al.  Noninvasive staging of non-small cell lung cancer: a review of the current evidence. , 2003, Chest.

[23]  G Antoch,et al.  Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. , 2003, Acta medica Austriaca.

[24]  S. Eustace,et al.  Whole-body Magnetic Resonance Imaging: Techniques, Clinical Indications, and Future Applications , 2001, Seminars in musculoskeletal radiology.

[25]  S. Schoenberg,et al.  Staging of invasive cervical carcinoma and of pelvic lymph nodes by high resolution MRI with a phased-array coil in comparison with pathological findings. , 1998, Journal of computer assisted tomography.

[26]  F L Bookstein,et al.  Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. , 1985, AJR. American journal of roentgenology.

[27]  Gerald Antoch,et al.  Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. , 2002, AJR. American journal of roentgenology.

[28]  B. Gross,et al.  Upper abdominal lymph nodes: criteria for normal size determined with CT. , 1991, Radiology.

[29]  R. Wahl,et al.  Initial experience with oral contrast in PET/CT: phantom and clinical studies. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  M. Harisinghani,et al.  MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (combidex): Preliminary observations , 1997, Journal of magnetic resonance imaging : JMRI.

[31]  O. Schober,et al.  Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. , 2001, AJR. American journal of roentgenology.

[32]  Ying Lu,et al.  Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. , 2002, Radiology.

[33]  Diego R. Martín,et al.  Comparison of MR and PET imaging for the evaluation of liver metastases , 2003, Journal of magnetic resonance imaging : JMRI.

[34]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[35]  C. Haagensen.  The Lymphatics in cancer , 1972 .

[36]  Gerald Antoch,et al.  Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[37]  D K Owens,et al.  Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. , 2001, JAMA.

[38]  J. Deslauriers,et al.  Clinical and surgical staging of non-small cell lung cancer. , 2000, Chest.

[39]  P. Mikosch,et al.  Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods , 2001, European Journal of Nuclear Medicine.

[40]  W. Heindel,et al.  FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  Townsend,et al.  7. Survey of Results of Whole Body Imaging Using the PET/CT at the University of Pittsburgh Medical Center PET Facility. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[42]  H. Harnsberger,et al.  Computed tomography of cervical and retropharyngeal lymph nodes: normal anatomy, variants of normal, and applications in staging head and neck cancer. Part I: normal anatomy. , 1983, Radiology.

[43]  S. Schoenberg,et al.  Imaging of lung cancer with CT, MRT and PET. , 2001, Lung cancer.

[44]  F. Fazio,et al.  Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results , 2003, The Lancet.